J. Goldman & CO LP Galmed Pharmaceuticals Ltd. Transaction History

J. Goldman & CO LP

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2018 Aug 14, 2018	SELL	$5.04 - $17.96 $131,040 - $466,960	-26,000 Closed	0 $0
Q1 2018 May 15, 2018	SELL	$5.12 - $11.77 $185,344 - $426,074	-36,200 Reduced 58.2%	26,000 $145,000
Q4 2017 Feb 14, 2018	BUY	$6.78 - $9.32 $421,716 - $579,704	62,200	62,200 $569,000

Ticker GLMD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 25,088,400
Market Cap $7.53M
Description
Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or t...

Get notified when there are updates to the investment portfolio of J. Goldman & CO LP, based on Form 13F filings with the SEC.

Stay updated on J. Goldman & CO LP with notifications on news.